KaydedilenlerDerginizi ekleyin

Dergiler / Erciyes Medical Journal / 2021 / Cilt: 43 - Sayı: 2

COVID-19 Disease and Interferon-γ: Has it aProtective Impact on Mortality?

Abbas Ali HUSSEİNİ
Anton Abdulbasah KAMİL
Mohammad Reza ALOUDAL
Sayfa
116–121
Yayın Tarihi
2022-10-11
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Concerning COVID-19 cases/million population (1MP) andmortality, there are significant differences between countries with and without BCG vaccination programs (p-value

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:The complex coincidence of several immunopathological, socio-cultural, and health infrastructure factors may affect theCOVID-19 related mortality among different populations.
📊
Temel Bulgular & Veri:Recently limited ecological and clinical studies have sparked controversy among researchers about theprotective impact of the non-specific effect of routinely used Bacille Calmette-Guerin (BCG), Hepatitis A virus (HAV), andinfluenza (Flu) vaccines or their natural infections against COVID-19.
💡
Sonuç & Katkı:Concerning COVID-19 cases/million population (1MP) andmortality, there are significant differences between countries with and without BCG vaccination programs (p-value
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

The complex coincidence of several immunopathological, socio-cultural, and health infrastructure factors may affect theCOVID-19 related mortality among different populations. The impact of the age on disease progression has been confirmedin several studies. Recently limited ecological and clinical studies have sparked controversy among researchers about theprotective impact of the non-specific effect of routinely used Bacille Calmette-Guerin (BCG), Hepatitis A virus (HAV), andinfluenza (Flu) vaccines or their natural infections against COVID-19. In the present study, variables, including BCG vaccina tion coverage, HAV prevalence, and population age distributions, from 59 countries were analyzed to examine their potentialassociation with COVID-19 infection and related mortality rate. Concerning COVID-19 cases/million population (1MP) andmortality, there are significant differences between countries with and without BCG vaccination programs (p-value

🔖

Bu Makaleye Atıf Yap

HUSSEİNİ, A. A., KAMİL, A. A., ALOUDAL, M. R. (2022). COVID-19 Disease and Interferon-γ: Has it aProtective Impact on Mortality?. Erciyes Medical Journal, Cilt: 43 - Sayı: 2, 116–121. https://ajindex.com/articles/502325

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Husseini AA, Kamil AA. Estimating COVID-19 Dynamics in Afghanistan. Erciyes Med J 2020; 42(4): 468–73. doi: 10.14744/ etd.2020.80270. [Epub ahead of print]
  2. European Centre for Disease Prevention and Control. “Situation updates on COVID-19”. Available from: URL: https://www.ecdc.europa.eu/en. Accessed Jun 15, 2020
  3. Gaythorpe K, Imai N, Cuomo-Dannenburg G, Baguelin M, Bhatia S, Boonyasiri A, et al. Report 8: Symptom progression of COVID-19. Available from: URL:
  4. Miller A, Reandelar MJ, Fasciglione K, Roumenova V, Li Y, Otazu GH. Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study. MedRxiv. 2020 March 28. doi: 10.1101/2020.03.24.20042937. [Epub ahead of print]
  5. Gursel M, Gursel I. Is global BCG vaccination-induced trained immunity relevant to the progression of SARS-CoV-2 pandemic? Allergy. 2020 April 27. doi: 10.1111/all.14345 [Epub ahead of print]
  6. Worldometer. Coronavirus update (live), 2020. Available from: URL: https://www.worldometers.info/coronavirus/?utm_campaign=homeADemocracynow(2020)%20dvegas1? Accessed Jun 15, 2020
  7. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395(10229): 1054–62
  8. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 2020; 146(1): 110–18
  9. Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. Crit Care 2020; 24(1): 108
  10. Center for Disease Control and Prevention. COVID-19 Response Team. Severe Outcomes among Patients with Coronavirus Disease 2019 (COVID-19) - United States, February 12-March 16, 2020. Morbidity Mortality Weekly Report. Weekly 2020; 69(12): 343–6
  11. Zhang J, Wang X, Jia X, Li J, Hu K, Chen G, et al. Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China. Clin Microbiol Infect 2020; 26(6): 767–72
  12. Sarialioglu F, Belen Apak FB, Haberal M. Can Hepatitis A Vaccine Provide Protection Against COVID-19?. Exp Clin Transplant 2020; 18(2): 141–3
  13. Horns F, Dekker CL, Quake SR